Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
142
resultados
Última actualización
24/04/2025 [06:58:00]
Resultados 50 a 75 de 142
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN119223942A
本发明公开了一种磁性水凝胶包裹细菌生物传感器平台与应用，属于合成生物学及临床诊断领域。该水凝胶递送回收体系包括水凝胶包裹的全细胞生物传感器和磁性微粒，其中，所述水凝胶由海藻酸钠和氯化钙构建，所述生物传感器为感应血红素的细菌。更具体地，本发明是使用海藻酸钠水凝胶封装工程细菌YES601和磁性Fe3O4微粒形成磁性水凝胶微球，作为生物传感器递送至肠道可以感应血红素而发光，再通过磁性吸附的方式从粪便中高效回收完整微球进行检测，提高了全细胞生物传感器检测肠道出血效率以及安全性。本发明提供的水凝胶递送回收体系整体设计优化策略可以提高诊断效率和实际应用价值。
Resumen de: CN119220678A
The invention relates to the technical field of biology, in particular to a kit related to colitis and proctitis malignant transformation, which comprises an intelligent system and a top cover, a semiconductor chilling plate is arranged at the bottom of the top cover, and a cooling fin is arranged at the top of the top cover; one side of the top cover is rotationally connected with a box body; a plurality of partition plates are fixedly connected into the box body and divide the interior of the box body into a plurality of containing cavities, and fixing assemblies are arranged on the side walls of the containing cavities. The miRNA marker related to the malignant transformation of colitis and proctitis comprises a miRNA marker body, and the miRNA marker body is one or more of miR-138-5p, miR-145-5p, miR-146a-5p, miR-150-5p, miR-146a, miR-27a, miR-29a, miR-20a and miR-21. The miRNA marker can be used for detecting the malignant transformation of colitis and proctitis. A detection agent is fixed through an elastic stretching plate and a magnet, so that the possibility that the detection agent is damaged is reduced; the interior of the kit is cooled through a semiconductor chilling plate, so that a detection agent and a detection plate can be stored for a long time; high-throughput detection of the miRNA marker is realized through the detection plate, and the detection efficiency is improved.
Resumen de: US2024425923A1
Described herein are systems and methods for stratifying intestinal mononuclear phagocytes (MNP) expression profiles in subjects with an inflammatory bowel disease (IBD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: FI20225151A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Resumen de: CN119183380A
The present disclosure relates to: a method for treating IBD using digestive tract content or excreta modified with an IgA antibody, a composition, and a method for producing the same; a method for obtaining an IgA antibody that makes the flora in the digestive tract of an IBD patient sound; methods, compositions, and methods of making the same for modifying the contents or excreta of the digestive tract of an IBD patient using an IgA antibody; a method for testing a patient treated with an IBD therapeutic agent containing digestive tract contents or excreta using a diagnostic agent containing an IgA antibody; a composition; and a method for producing the composition.
Resumen de: KR20240175341A
본 발명은 ATP의 검출능을 갖는 효모, ATP의 검출방법 및 ATP의 검출방법에 의한 염증성 장 질환 진단용 바이오마커에 관한 것으로, 본 발명의 반딧불이 루시페라제를 발현하는 재조합 효모를 기반으로 하는 ATP의 검출방법인 전세포 기반 센서 시스템을 활용하여 ATP를 쉽게 검출할 수 있고 이를 이용하여 비침습 적으로 염증성 장 질환(IBD)과 같은 ATP 관련 질병의 진단에 유용하게 활용할 수 있다.
Resumen de: CN119162304A
The invention discloses a Crohn disease enteric microorganism marker and application thereof and a method for constructing a Crohn disease detection model.The Crohn disease enteric microorganism marker is characterized in that enteric microorganisms related to Crohn disease are extracted from metagenome data of samples of Crohn disease patients and healthy people; the method comprises the following steps: establishing a random forest model for diagnosing the Crohn disease through the intestinal microbial marker of the Crohn disease, and evaluating to obtain a Crohn disease detection model; according to the method provided by the invention, the treatment effect can be evaluated, the treatment scheme can be adjusted in time, and a new tool is provided for prognosis evaluation of a patient; the specific intestinal microbial marker aiming at the Crohn's disease is found and applied, so that the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of the Crohn's disease are improved, the understanding of the Crohn's disease is deepened, and the development of microbiomics in clinical application is promoted; new biomarkers can be found easily, and new biomarkers or therapeutic targets can be found.
Resumen de: US2024415899A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: WO2024256789A1
The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg/ml and interleukin 8 (IL-8) at a concentration of more than 150 pg/ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg/ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg/ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Resumen de: TW202448503A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: CN119120778A
The invention relates to the technical field of virus detection, and particularly discloses a method for detecting a chicken infectious bursal disease virus based on RAA-CRISPR/Cas13a-LFD. The sequence of the upstream primer for detecting the infectious bursal disease virus is as shown in SEQ ID NO: 1, the sequence of the downstream primer is as shown in SEQ ID NO: 2, and the sequence of the specific crRNA is as shown in SEQ ID NO: 3. According to the method provided by the invention, the target gene can be effectively amplified by reacting for 40 minutes under the condition of 37 DEG C, and a test result can be judged through LFD naked eye observation; the specificity is good, and the lowest detection limit can reach 100 copies/mu L; good repeatability and stability are realized; the coincidence rate of clinical detection reaches 98.33%, and the kit can be used for clinical rapid diagnosis and prevention and control of the infectious bursal disease (IBD).
Resumen de: CN119124792A
The invention discloses a two-dimensional titanium-containing nanosheet decorated with nanoscale iron-containing particles and application of the two-dimensional titanium-containing nanosheet in plasma exosome separation and Crohn disease diagnosis, and belongs to the technical field of biological detection based on exosomes. The prepared two-dimensional titanium-containing nanosheet decorated with the nanoscale iron-containing particles has strong interaction with phospholipid on the surface of the exosome, and efficient adsorption and separation of the exosome in a plasma sample to be detected can be achieved. In addition, the two-dimensional titanium-containing nanosheet further has strong ultraviolet absorption and high conductivity, exosome metabolites can be ionized, a remarkable mass spectrum signal is generated, and rapid diagnosis of Crohn's disease is achieved through an LDI-TOF MS analysis and detection technology.
Resumen de: AU2024266697A1
Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Resumen de: WO2024252368A2
The invention provides methods and compositions related to methods for determining whether a human subject having ulcerative colitis will respond to treatment with a humanized antibody having binding specificity for human α4β7 integrin for treating ulcerative colitis. The invention provides response markers that can be used to identify responders of ulcerative colitis.
Resumen de: WO2024252267A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: CN119097714A
本发明提供了促炎基质4细胞抑制剂和检测MMP1的物质的应用，属于生物医药技术领域。其中，所述促炎基质4细胞抑制剂可用于制备治疗肠上皮再生障碍、先天性巨结肠、小肠结肠炎或先天性巨结肠相关小肠结肠炎的药物。所述检测MMP1的物质可用于制备预测先天性巨结肠相关小肠结肠炎的产品。本发明首次发现了促炎基质4细胞在先天性巨结肠患者的扩张段肠组织中表现出特异性，而这些细胞无法维持健康类器官的生长；然而，通过使用促炎基质4细胞抑制剂，可以恢复上皮类器官的生长。此外，促炎基质4细胞的出现在先天性巨结肠相关小肠结肠炎发作之前，这为预测和治疗该疾病提供了有力的依据。因此本发明在生物医药技术领域具有广泛的应用前景。
Resumen de: CN119104708A
The invention discloses application of kynurenine, formyl-5-hydroxykynurenine and 3-methoxy-4-hydroxyphenyl glycol as serum biomarkers for evaluating the curative effect of Crohn's disease, and relates to the technical field of medical treatment. In particular to application of kynurenine, formyl-5-hydroxykynurenine and 3-methoxy-4-hydroxyphenyl glycol as serum markers in preparation of a kit for evaluating the treatment effect of the mesenchymal stem cells on the Crohn disease. On the basis of an isotope labeled liquid chromatography-mass spectrometry technology, the therapeutic effectiveness biomarker is screened by detecting the change of serum metabolites before and after the placenta-derived mesenchymal stem cells treat a mouse with Crohn disease, and the diagnostic efficiency of the therapeutic effectiveness biomarker is evaluated; and data support is provided for clinical transformation of the mesenchymal stem cells for treating Crohn's disease.
Resumen de: CN119074963A
The invention relates to the technical field of relieving of hepatotoxicity caused by triptolide, particularly provides a method for reducing hepatotoxicity induced by triptolide based on ergothioneine, and provides application of ergothioneine in preparation of drugs for reducing hepatotoxicity of triptolide. According to the application disclosed by the invention, medicinal compositions, namely triptolide and ergothioneine, are jointly used on a dextran sulfate sodium salt induced inflammation animal model, so that colon and liver tissues in the inflammation animal model are analyzed. The result shows that the ergothioneine does not interfere with the drug effect of the triptolide, and the hepatotoxicity induced by the triptolide can be obviously improved; the ergothioneine disclosed by the invention has a guiding effect on inflammatory bowel diseases, lupus nephritis, asthma, rheumatoid arthritis, nephrotic syndrome, eczema, psoriasis or tumors which are treated by triptolide.
Resumen de: CN119086926A
本发明涉及CLCA1蛋白作为表征双歧杆菌丰度的标志物的应用，还涉及一种表征双歧杆菌丰度的方法，其通过检测样本中的CLCA1蛋白水平从而评估双歧杆菌的丰度。本发明基于宿主肠道蛋白CLCA1和双歧杆菌属细菌细胞膜上的atpH蛋白特异性互作从而促进双歧杆菌的定植的作用机制，首次提出通过检测粪便中CLCA1的丰度来间接反应肠道双歧杆菌的丰度，该方法具有快速、便捷、无需基因组DNA提取步骤、对人员设备要求较低并且成本低的优势；此外，通过检测疑似患者粪便中CLCA1的丰度，可为与肠道双歧杆菌的丰度降低相关的疾病的诊疗提供一定的参考依据。
Resumen de: MX2024013561A
Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation. Described herein are compositions and methods that, in some embodiments, are specifically configured to treat different types of constipation. In particular, described herein are compositions and methods for treating IBS-C, opioid induced constipation, and chronic idiopathic constipation. In addition to treating the symptom of constipation, these embodiments of the compositions and methods described herein are configured to address specific etiologies and/or pathophysiologies associated with the constipation types of IBS-C, opioid induced constipation, and chronic idiopathic constipation.
Resumen de: WO2024243687A1
Methods of selecting prebiotics, optionally resistant starch, optimized for an individual with inflammatory bowel disease and methods of treating individuals with the selected prebiotics are provided.
Resumen de: JP2024169624A
To provide a method for inspecting ulcerative colitis which is useful for determining a disease state of ulcerative colitis.SOLUTION: A method for producing a strain sample derived from a subject in which the strain diversity and/or the number of strains in the sample of the subject are maintained includes: 1) a process of adding the sample of the subject to a culture medium; 2) a process of performing an operation to bring pH of the culture medium to 6.2 to 6.7 in starting the cultivation if necessary; and 3) a process of culturing the sample after starting the cultivation without performing an operation intended to maintain pH of the culture medium. Preferably, the method includes A) a process of performing sterilization of the culture medium and aeration to anaerobic gas and/or B) a process of suspending the sample to ascorbic acid-added phosphate buffer, before 1).SELECTED DRAWING: Figure 1
Resumen de: WO2024246589A1
The invention relates to an isolated antibody or a fragment thereof that binds to the SKECF peptide of the sST2 protein. In particular, the invention relates to a short variable fragment of an antibody (scFv) and to a human antibody with affinity for the sST2 molecule, to nucleic acids encoding the same, to the pharmaceutical compositions containing the same, and to the use thereof to treat inflammatory diseases, such as ulcerative colitis.
Nº publicación: US2024397984A1 05/12/2024
Solicitante:
ARISTA CEREAL TECH PTY LIMITED [AU]
Arista Cereal Technologies Pty Limited
Resumen de: US2024397984A1
Provided are food and drink ingredients produced from wheat grain which has a low level (2-30%) of total starch branching enzyme II activity and an amylose content in the starch of at least 50% (w/w), and processes for producing and using the ingredients. Also provided are foods produced from the ingredients which may be used in humans to improve one or more parameters of metabolic health, bowel health or cardiovascular health.
BOPI
Sede Electrónica
